Crohn’s strictures open with anti-mycobacterial antibiotic therapy: A retrospective review

Table 1 Profile of the forty patients with Crohn’s disease presenting at pre-treatment

	Pre-treatment cohort (n = 40)
Demographics
Age at AMAT [yr (IQR)]	27 (24-39)
Sex [M (%)]	22 (55%)
Duration of disease [yr (IQR)]	3 (1-8)
Time between diagnosis and stricture [yr (IQR)]	2.5 (0-6)
Number of strictures
Single strictures, n (%)	34 (85)
Multiple strictures, n (%)	6 (15)
Symptoms
Y, n (%)	39 (98)
Abdominal pain, n (%)	31 (78)
Diarrhoea, n (%)	21 (53)
Fatigue, n (%)	6 (15)
Weight loss, n (%)	5 (13)
Vomiting, n (%)	4 (10)
Constipation, n (%)	2 (5)
Pathology
CRP [mg/L (IQR)]	19 (11-92)
ESR [mm/h (IQR)]	12 (5-27)
Area of involvement
ICV, n (%)	19 (48)
TI, n (%)	20 (50)
ICV + TI, n (%)	1 (3)
Concomitant medication
Y, n (%)	31 (78)
N, n (%)	9 (23)

AMAT: Anti-mycobacterial antibiotic therapy; IQR: Interquartile range; M: Male; Y: Yes; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; ICV: Ileocecal valve; TI: Terminal ileum; N: No.

Table 2 Comparison of stricture outcomes in the thirty patients that returned for follow-up

	CR (n = 20)	PR + NR (n = 10)	P value
Demographics
Age at AMAT [yr (IQR)]	28 (24-32)	26 (25-47)	0.66
Sex (M)	11	4	0.70
Duration of disease [yr (IQR)]	4 (1-8)	2 (1-4)	0.45
Time between diagnosis and stricture [yr (IQR)]	3 (0-6)	1.5 (0-3)	0.54
Stricture outcome
Single stricture, n (%)	19 (95)	7 (70)	0.10
Multiple strictures, n (%)	1 (5)	3 (30)
Clinical outcome
Clinical response, n (%)	16 (80)	5 (50)	0.12
No clinical response, n (%)	4 (20)	5 (50)
Pathology
CRP [mg/L (IQR)]	4 (3-10)	6 (4-8)	0.71
ESR [mm/h (IQR)]	5 (2-9)	6 (4-11)	0.86
Area of involvement
ICV, n (%)	8 (40)	4 (40)
TI, n (%)	12 (60)	5 (50)
ICV + TI, n (%)	0 (0)	1 (10)
Duration of AMAT for stricture outcome
≤ 12 mo, n (%)	10 (50)	3 (30)	0.44
> 12 mo, n (%)	10 (50)	7 (70)

Clinical outcomes: (1) Clinical response with complete resolution (CR): n = 16 (7, asymptomatic; 9, improved); (2) clinical response with partial resolution (PR) + no resolution (NR): n = 5 (1, asymptomatic; 4, improved); (3) no clinical response with CR: n = 4 (4, no change); and (4) no clinical response with PR + NR: n = 5 (4, no change; 1, worsened). CR: Complete resolution; PR: Partial resolution; NR: No resolution; AMAT: Anti-mycobacterial antibiotic therapy; IQR: Interquartile range; M: Male; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; ICV: Ileocecal valve; TI: Terminal ileum.

Table 3 Concomitant therapy of the thirty patients on anti-mycobacterial antibiotic therapy that returned for follow-up

	CR (n = 20)	PR + NR (n = 10)	P value
Concomitant biologic medication
Y, n (%)	3 (15)	3 (30)	0.37
N, n (%)	17 (85)	7 (70)
Concomitant steroid medication
Y, n (%)	13 (65)	3 (30)	0.12
N, n (%)	7 (35)	7 (70)
Concomitant IMD medication
Y, n (%)	12 (60)	1 (10)	0.02
N, n (%)	8 (40)	9 (90)
Concomitant 5-ASA medication
Y, n (%)	13 (65)	4 (40)	0.26
N, n (%)	7 (35)	6 (60)

CR: Complete resolution; PR: Partial resolution; NR: No resolution; Y: Yes; N: No; IMD: Immunomodulator; 5-ASA: 5-Aminosalicylate.